Clazosentan Sodium

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H21N9O6S.2Na
Molecular Weight	621.535
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].COC1=C(OC2=C([N-]S(=O)(=O)C3=NC=C(C)C=C3)N=C(N=C2OCCO)C4=CC(=NC=C4)C5=NN=N[N-]5)C=CC=C1

InChI

InChIKey=PZNSONUYVNYXJZ-UHFFFAOYSA-N

InChI=1S/C25H21N9O6S.2Na/c1-15-7-8-20(27-14-15)41(36,37)32-24-21(40-19-6-4-3-5-18(19)38-2)25(39-12-11-35)29-22(28-24)16-9-10-26-17(13-16)23-30-33-34-31-23;;/h3-10,13-14,35H,11-12H2,1-2H3;;/q-2;2*+1

HIDE SMILES / InChI

Molecular Formula	C25H22N9O6S
Molecular Weight	576.564
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21640651 | https://clinicaltrials.gov/ct2/show/NCT03585270 | https://www.ncbi.nlm.nih.gov/pubmed/9399983 | https://www.idorsia.com/about-idorsia/idorsia-today/our-pipeline

Clazosentan is an endothelin receptor antagonist, developed by the Swiss pharmaceutical company Actelion, and licensed to its spin-off, Idorsia. The drug was designed to inhibit endothelin-mediated cerebral vasospasm and associated delayed ischaemic neurological deficit. The drug has been investigated in a phase III clinical trials in patients with aneurysmal subarachnoid hemorrhage. Clazosentan at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome. Clinical investigation of a higher dose of the drug is underway.

Approval Year

PubMed

Title	Date	PubMed
Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.	2005 Jul	16121967
Vasospasm.	2005 Jul	16121964
Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: effect on endothelin(B) receptor-mediated relaxation.	2005 Jun	16028771
Effect of gender on the tolerability, safety and pharmacokinetics of clazosentan following long-term infusion.	2007	17914898
Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.	2007 Feb	16636870
[Systemic treatments of the vasospasm].	2007 Nov	17933488
Influence of ethnic origin and sex on the pharmacokinetics of clazosentan.	2007 Nov	17906281
IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice.	2008 Feb 19	18250323
Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage.	2008 Nov	18922111
Effect of endothelin-receptor antagonists on delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage remains unclear.	2009 Dec	19875735
Delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: is angiographic vasospasm an epiphenomenon?	2009 Feb	19074477
Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials.	2010 Dec	20838933

Patents

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:37:20 GMT 2023` Edited by `admin` on `Fri Dec 15 16:37:20 GMT 2023`
Record UNII	0L77PK62L1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Clazosentan Sodium

Official Name

English

CLAZOSENTAN SODIUM [USAN]

Common Name

English

Clazosentan sodium [WHO-DD]

Common Name

English

CLAZOSENTAN SODIUM [JAN]

Common Name

English

CLAZOSENTAN DISODIUM SALT

Common Name

English

Disodium N-{2-[2-(1H-tetrazol-5-yl)pyridin-4-yl]-6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)pyrimidin-4-yl}-5-methylpyridine-2-sulfonamide

Systematic Name

English

CLAZOSENTAN DISODIUM SALT [MI]

Common Name

English

2-Pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1Htetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-(1-methyl)-, disodium salt (1:2)

Common Name

English

ACT-108475A

Code

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/03/182